Administration of Drug for Acute Respiratory Distress Syndrome Can Be Detrimental

Recommend to others!

Medications are invented by researchers and scientist to cure and improve treatment outcomes of many individuals who are affected by certain illnesses or diseases. Also, accompanying these medications are issues on safety and effectiveness, hence, further studies and examination of many drugs right now are being done in order to rule out any untoward effects of these medications to the health of many individuals who are actually receiving these medications.

These drugs before they are released into the mainstream market should undergo series of tests and clinical trial conducted by government institutions. Results should be positive for these drugs to be considered safe and effective. Recently, a drug which is administered to patients with Acute Respiratory Distress Syndrome (ARDS) has been stopped because of proofs which show that the drug does not provide better treatment results and increases the risk of death among patients, according to a new study.

The new study which was published online in the The Lancet tackled about the examination of the safety and effectiveness of the drug Salbutamol which is administered intravenously to patients with ARDS. The study showed that the drug was associated to increased risk of deaths among patients, and thus, its administration must be stopped.

The new British study involved the analysis and examination of data gathered from about 326 patients who were actually suffering from ARDS. These study participants received either the drug salbutamol or a placebo for about 7 days of treatment. However, the treatment was stopped after the researchers discovered that about 34 per cent of the study participants who belong in the group treated with salbutamol tantamount to about 55 individuals had died. That is compared to about 23 per cent or 38 individuals who belong to the placebo group.

Moreover, researchers quantified that the overall death rate among the group treated with salbutamol is significantly higher as compared to the placebo group. The differences of death rate are about 47 per cent higher. In addition, researchers also noted that those individuals who belong to the salbutamol group had lesser days which are considered ventilator free, and lesser organ failure-free days as to those who belong in the group treated with placebo.

According to Fang Gao Smith and Gavin Perkins of the University of Warwick, and colleagues: “Our findings show that intravenous salbutamol given to patients with early ARDS significantly increased 28-day mortality, and reduced ventilator-free days and duration of organ support compared with those given placebo.”




Speak Your Mind


Current day month ye@r *